823 related articles for article (PubMed ID: 16336326)
1. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
Lehmann J; Franzaring L; Thüroff J; Wellek S; Stöckle M
BJU Int; 2006 Jan; 97(1):42-7. PubMed ID: 16336326
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
Lehmann J; Retz M; Wiemers C; Beck J; Thüroff J; Weining C; Albers P; Frohneberg D; Becker T; Funke PJ; Walz P; Langbein S; Reiher F; Schiller M; Miller K; Roth S; Kälble T; Sternberg D; Wellek S; Stöckle M;
J Clin Oncol; 2005 Aug; 23(22):4963-74. PubMed ID: 15939920
[TBL] [Abstract][Full Text] [Related]
4. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
Birtle AJ; Huddart RA
BJU Int; 2006 Jun; 97(6):1348; author reply 1348-50. PubMed ID: 16686740
[No Abstract] [Full Text] [Related]
5. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
8. [Prognosis in pT3b infiltrating tumors of the bladder treated by adjuvant chemotherapy].
Sahwi A; Robert M; Delbos O; Legouffe E; Guiter J; Navratil H
Prog Urol; 1998 Dec; 8(6):1007-11. PubMed ID: 9894259
[TBL] [Abstract][Full Text] [Related]
9. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.
Freiha F; Reese J; Torti FM
J Urol; 1996 Feb; 155(2):495-9; discussion 499-500. PubMed ID: 8558644
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy.
Lehmann J; Retz M; Stöckle M
World J Urol; 2002 Aug; 20(3):144-50. PubMed ID: 12196897
[TBL] [Abstract][Full Text] [Related]
12. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
Matsui Y; Nishiyama H; Watanabe J; Teramukai S; Ono Y; Ohshima S; Fujimoto K; Hirao Y; Fukushima M; Ogawa O
Int J Clin Oncol; 2005 Apr; 10(2):133-8. PubMed ID: 15864700
[TBL] [Abstract][Full Text] [Related]
13. Can patient selection for bladder preservation be based on response to chemotherapy?
Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
[TBL] [Abstract][Full Text] [Related]
14. Surgical factors influence bladder cancer outcomes: a cooperative group report.
Herr HW; Faulkner JR; Grossman HB; Natale RB; deVere White R; Sarosdy MF; Crawford ED
J Clin Oncol; 2004 Jul; 22(14):2781-9. PubMed ID: 15199091
[TBL] [Abstract][Full Text] [Related]
15. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
[TBL] [Abstract][Full Text] [Related]
16. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study.
Walz J; Shariat SF; Suardi N; Perrotte P; Lotan Y; Palapattu GS; Gupta A; Bastian PJ; Rogers CG; Vazina A; Amiel GE; Sagalowsky AI; Schoenberg M; Lerner SP; Karakiewicz PI
BJU Int; 2008 Jun; 101(11):1356-61. PubMed ID: 18454792
[TBL] [Abstract][Full Text] [Related]
18. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
Kuroda M; Kotake T
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer.
Nieuwenhuijzen JA; Bex A; Meinhardt W; Kerst JM; Schornagel JH; VAN Tinteren H; Horenblas S
J Urol; 2005 Jul; 174(1):80-5. PubMed ID: 15947583
[TBL] [Abstract][Full Text] [Related]
20. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
